Biochemical cardiovascular risk factors after hypertensive pregnancy disorders: A systematic review and meta-analysis: Editorial comment

Obstetrical and Gynecological Survey

Volumn 67, Issue 12, 2012, Pages 793-809

  Hermes, Wietske ^a   Ket, Johannes C F ^b   Van Pampus, Maria G ^c   Franx, Arie ^d   Veenendaal, Marjolein V E ^e   Kolster, Clara ^f   Tamsma, Jouke T ^g   Bloemenkamp, Kitty W M ^f   Ponjee, Gabrielle ^a   Van Der Hout, Evelien ^e   Ten Horn, Hilde ^e   Loix, Stéphanie ^h   Mol, Ben Willem ^e   De Groot, Christianne J M ^b  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g University Medical Center   (Netherlands)

^h MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

BIOCHEMISTRY; BLOOD ANALYSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ECLAMPSIA; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; HIGH RISK PREGNANCY; HUMAN; INSULIN BLOOD LEVEL; MATERNAL HYPERTENSION; MICROALBUMINURIA; PREECLAMPSIA; PREGNANCY DISORDER; PRIMARY PREVENTION; PROTEINURIA; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ALBUMINURIA; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; INSULIN; PREGNANCY; RISK FACTORS; TRIGLYCERIDES;

EID: 84872876105     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31827682fc     Document Type: Review

References (55)

1. ACOG Technical Bulletin. Hypertension in pregnancy. Number 219-January 1996 (replaces no. 91, February 1986). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1996;53: 175-183.
2. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
3. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ. 2002;325:157-160.
4. McDonald SD, Malinowski A, Zhou Q, et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156:918-930.
5. Burell G, Granlund B. Women's hearts need special treatment. Int J Behav Med. 2002;9:228-242.
6. Haukkamaa L, Salminen M, Laivuori H, et al. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol. 2004;93:805-808.
7. Irgens HU, Reisaeter L, Irgens LM, et al. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323:1213-1217.
8. Jonsdottir LS, Arngrimsson R, Geirsson RT, et al. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand. 1995;74:772-776.
9. Ramsay JE, StewartF, Greer IA, et al.Microvasculardysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG. 2003;110:1029-1031.
10. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001;357:2002-2006.
11. Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326:845.
12. Brown MA, Lindheimer MD, De SM, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20: IXYXIV.
13. Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol. 2005;105:402-410.
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
15. Bar J, Kaplan B, Wittenberg C, et al. Microalbuminuria after pregnancy complicated by pre-eclampsia. Nephrol Dial Transplant. 1999;14:1129-1132.
16. Barden AE, Beilin LJ, Ritchie J, et al. Does a predisposition to the metabolic syndrome sensitize women to develop preeclampsia? J Hypertens. 1999;17:1307-1315.
17. Berends AL, de Groot CJ, Sijbrands EJ, et al. Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension. 2008;51:1034-1041.
18. Chambers JC, Fusi L, Malik IS, et al. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 2001;285: 1607-1612.
19. Forest JC, Girouard J, Masse J, et al. Early occurrence of metabolic syndrome after hypertension in pregnancy. Obstet Gynecol. 2005;105:1373-1380.
20. Freeman DJ, McManus F, Brown EA, et al. Short-and longterm changes in plasma inflammatory markers associated with preeclampsia. Hypertension. 2004;44:708-714.
21. Girouard J, Giguere Y, Moutquin JM, et al. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension. 2007;49:1056-1062.
22. He S, Silveira A, Hamsten A, et al. Haemostatic, endothelial and lipoprotein parameters and blood pressure levels in women with a history of preeclampsia. Thromb Haemost. 1999;81: 538-542.
23. Hubel CA, Snaedal S, Ness RB, et al. Dyslipoproteinaemia in postmenopausal women with a history of eclampsia. BJOG. 2000;107:776-784.
24. Hubel CA, Powers RW, Snaedal S, et al. C-reactive protein is elevated 30 years after eclamptic pregnancy. Hypertension. 2008;51:1499-1505.
25. Innes KE, Weitzel L, Laudenslager M. Altered metabolic profiles among older mothers with a history of preeclampsia. Gynecol Obstet Invest. 2005;59:192-201.
26. Laivuori H, Tikkanen MJ, Ylikorkala O. Hyperinsulinemia 17 years after preeclamptic first pregnancy. J Clin Endocrinol Metab. 1996;81:2908-2911.
27. Lampinen KH, Ronnback M, Groop PH, et al. A relationship between insulin sensitivity and vasodilation in women with a history of preeclamptic pregnancy. Hypertension. 2008;52: 394-401.
28. Manten GT, Sikkema MJ, Voorbij HA, et al. Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction. Hypertens Pregnancy. 2007;26:39-50.
29. Nisell H, Erikssen C, Persson B, et al. Is carbohydrate metabolism altered among women who have undergone a preeclamptic pregnancy? Gynecol Obstet Invest. 1999; 48:241-246.
30. Paradisi G, Biaggi A, Savone R, et al. Cardiovascular risk factors in healthy women with previous gestational hypertension. J Clin Endocrinol Metab. 2006;91:1233-1238.
31. Portelinha A, Belo L, Cerdeira AS, et al. Lipid levels including oxidized LDL in women with history of preeclampsia. Hypertens Pregnancy. 2010;29:93-100.
32. Pouta A, Hartikainen AL, Sovio U, et al. Manifestations of metabolic syndrome after hypertensive pregnancy. Hypertension. 2004;43:825-831.
33. Sattar N, Ramsay J, Crawford L, et al. Classic and novel risk factor parameters in women with a history of preeclampsia. Hypertension. 2003;42:39-42.
34. Smith GN, Walker MC, Liu A, et al. A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol. 2009;200:58.
35. Wolf M, Hubel CA, Lam C, et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab. 2004;89: 6239-6243.
36. Spaan JJ, Houben AJHM, Musella A, et al. Insulin resistance relates to microvascular reactivity 23 years after preeclampsia. Microvasc Res. 2010;80:417-421.
37. Libby G, Murphy DJ, McEwan NF, et al. Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort. Diabetologia. 2007;50:523-530.
38. Third Report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
39. Sarwar N, Sattar N, Gudnason V, et al. Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. Eur Heart J. 2007;28:2491-2497.
40. Defronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
41. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
42. Cerasola G, Cottone S, Mule G, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens. 1996;14:915-920.
43. Parving HH. Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens Suppl. 1996;14:S89YS93.
44. Pontremoli R. Microalbuminuria in essential hypertensionVits relation to cardiovascular risk factors. Nephrol Dial Transplant. 1996;11:2113-2115.
45. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
46. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969-975.
47. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
48. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342: 836-843.
49. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129-2138.
50. Meng YX, Ford ES, Li C, et al. Association of C-reactive protein with surrogate measures of insulin resistance among nondiabetic US from National Health and Nutrition Examination Survey 1999-2002. Clin Chem. 2007;53:2152-2159.
51. Yeh ET. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol. 2005; 28:408-412.
52. Chesley SC, Annitto JE, Cosgrove RA. The remote prognosis of eclamptic women. Sixth periodic report. Am J Obstet Gynecol. 1976;124:446-459.
53. Funai EF, Paltiel OB, Malaspina D, et al. Risk factors for preeclampsia in nulliparous and parous women: the Jerusalem perinatal study. Paediatr Perinat Epidemiol. 2005;19:59-68.
54. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in womenV2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404-1423.
55. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.